<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01513681</url>
  </required_header>
  <id_info>
    <org_study_id>AAI-US-136</org_study_id>
    <nct_id>NCT01513681</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study for Lamotrigine Tablets 200 mg Under Fed Condition</brief_title>
  <official_title>Single Dose, Two-way, Crossover, Oral Bioequivalence Study of Lamotrigine Tablets 200 mg With Lamictal® Tablets 200 mg in Healthy, Volunteers Under Fed Condition.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an single dose,two-way, crossover, oral bioequivalence study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was an single dose, two-way, crossover, oral bioequivalence study of Lamotrigine
      tablets 200 mg of Dr. Reddy's Laboratories Limited, India comparing with that of LAMICTAL®
      tablets 200 mg of GlaxoSmithKline Inc, in healthy, adult, human subjects under fed condition.
      20 subjects (14 male and 6 womens) are enrolled and completed the study. The washout period
      is 14 days between the two periods of the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2002</start_date>
  <completion_date type="Actual">November 2002</completion_date>
  <primary_completion_date type="Actual">November 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under curve (AUC)</measure>
    <time_frame>Pre-dose 0.25, 0.5,1,1.5,2,2.5,3,3.5,4,5,6,8,12,24,36,48,72,96,120 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Lamotrigine Tablets 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lamotrigine Tablets 200 mg of Dr. Reddy's Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lamictal® 200 mg Tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lamictal® 200 mg Tablets of GlaxoSmithKline Inc</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamotrigine</intervention_name>
    <description>Lamotrigine Tablets 200 mg</description>
    <arm_group_label>Lamotrigine Tablets 200 mg</arm_group_label>
    <arm_group_label>Lamictal® 200 mg Tablets</arm_group_label>
    <other_name>Lamictal® 200 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamictal®</intervention_name>
    <description>Lamictal® 200 mg Tablets</description>
    <arm_group_label>Lamotrigine Tablets 200 mg</arm_group_label>
    <arm_group_label>Lamictal® 200 mg Tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy males and females at least 18 years of age inclusive

          2. Informed of the nature of the study and given written informed consent

          3. Have a body weight within 15% of the appropriate range as defined in the 1983
             Metropolitan Life Company tables and weighing at least 100 lbs.

        Exclusion Criteria:

          1. Hypersensitivity to Lamotrigine (Lamictal®) or similar compounds or any history of
             seizures or clinically significant neurological conditions.

          2. Any history of a clinical condition which might affect drug absorption, metabolism or
             excretion

          3. Recent history of mental illness, drug addition,drug abuse or alcoholism

          4. Donation of greater than 500 ml of blood in the past 4 weeks prior to study dosing of
             difficulty in donating blood.

          5. Received an investigational drug within the 4 weeks prior to study dosing.

          6. Currently taking any prescription medication, except oral contraceptives, within the 7
             days prior to study dosing or over-the -counter medication within 3 days of study
             dosing. This prohibition does not include vitamins or herbal preparations taken as
             nutritional supplements for non-therapeutics indications as judged by the attending
             physician.

          7. Tobacco use (&gt;5 cigarettes per day) in the 3 months prior to study dosing.

          8. If female, the subjects is lactating or has a positive pregnancy test screening and
             prior to each of the two treatments periods. Females of child bearing potential must
             use a medical acceptable method of contraception throughout the entire study period
             and for one week after the study is completed. Medically acceptable methods or
             contraception that may be used by the subject and/or her partner are; oral
             contraceptives, progestin injection or implants, condom with spermicide, diaphragm
             with spermicide, IUD, vaginal spermicidal suppository, surgical sterilization of their
             partner(s) or abstinence. Females taking oral contraceptives must have taken them
             consistently for at least three months prior to receiving study medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Ralph Scallion, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AAI Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AAI Clinic</name>
      <address>
        <city>Quadrangle drive</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2002</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2012</study_first_submitted>
  <study_first_submitted_qc>January 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2012</study_first_posted>
  <last_update_submitted>January 17, 2012</last_update_submitted>
  <last_update_submitted_qc>January 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Lamotrigine</keyword>
  <keyword>crossover</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamotrigine</mesh_term>
    <mesh_term>Anticonvulsants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

